Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Florence T H Wu"'
Publikováno v:
PLoS Computational Biology, Vol 5, Iss 12, p e1000622 (2009)
Vascular endothelial growth factor (VEGF) is a potent cytokine that binds to specific receptors on the endothelial cells lining blood vessels. The signaling cascade triggered eventually leads to the formation of new capillaries, a process called angi
Externí odkaz:
https://doaj.org/article/cade83ac73f145ee89877213d35f5ee4
Publikováno v:
PLoS ONE, Vol 4, Iss 4, p e5108 (2009)
Vascular endothelial growth factor (VEGF), through its activation of cell surface receptor tyrosine kinases including VEGFR1 and VEGFR2, is a vital regulator of stimulatory and inhibitory processes that keep angiogenesis--new capillary growth from ex
Externí odkaz:
https://doaj.org/article/535c8d177efe416582c1171d841a00ae
Supplementary Methods, Glossary, Figure Legends 1-3 from Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215999e4b51339ed48832155ce894cd7
https://doi.org/10.1158/0008-5472.22386938.v1
https://doi.org/10.1158/0008-5472.22386938.v1
Supplementary Figure 1 from Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a0bc333de9a4469a8fecefdae3dbf9a
https://doi.org/10.1158/0008-5472.22386947.v1
https://doi.org/10.1158/0008-5472.22386947.v1
Supplementary Figure 3 from Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266b1ce3687fdd6ac725bb67c109cca7
https://doi.org/10.1158/0008-5472.22386941
https://doi.org/10.1158/0008-5472.22386941
Supplementary Tables 2-5 from Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::964b2af9223c12838e5c67bba41c107f
https://doi.org/10.1158/0008-5472.22386932.v1
https://doi.org/10.1158/0008-5472.22386932.v1
Supplementary Table 1 from Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f11e8693b2e90274c66bb01d0002e61
https://doi.org/10.1158/0008-5472.22386935.v1
https://doi.org/10.1158/0008-5472.22386935.v1
Supplementary Figure 2 from Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98d10fa1a93154ecb4856ae218f27eb6
https://doi.org/10.1158/0008-5472.22386944
https://doi.org/10.1158/0008-5472.22386944
Publikováno v:
EMBO Molecular Medicine
Anti‐angiogenic drugs targeting the VEGF pathway are most effective in advanced metastatic disease settings of certain types of cancers, whereas they have been unsuccessful as adjuvant therapies of micrometastatic disease in numerous phase III tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f198f8e669e1f45608f0194f3da46141
https://pubmed.ncbi.nlm.nih.gov/34125494
https://pubmed.ncbi.nlm.nih.gov/34125494
Autor:
Ping Xu, Marta Paez-Ribes, Shan Man, Robert S. Kerbel, Annabelle Chow, Kabir A. Khan, Janna Krüger, Florence T. H. Wu, Elizabeth Pham
Publikováno v:
British Journal of Cancer
Background There are phase 3 clinical trials underway evaluating anti-PD-L1 antibodies as adjuvant (postoperative) monotherapies for resectable renal cell carcinoma (RCC) and triple-negative breast cancer (TNBC); in combination with antiangiogenic VE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff73f5914ba6cffef92a9ce726e343c3
https://doi.org/10.1038/s41416-018-0297-1
https://doi.org/10.1038/s41416-018-0297-1